A citation-based method for searching scientific literature

Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma, James Christensen, Peter S Hammerman, Lynette M Sholl. J Clin Oncol 2016
Times Cited: 309



Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V Ivanova, Giulia C Leonardi, Bryan C Ulrich, Cloud P Paweletz, Paul T Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J Nagy, Richard B Lanman, Marzia Capelletti, Emily S Chambers, Amanda J Redig, Paul A VanderLaan, Daniel B Costa, Yu Imamura, Pasi A Jänne. Clin Cancer Res 2018
Times Cited: 31




List of shared articles



Times cited

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
Mariacarmela Santarpia, Marco Massafra, Vittorio Gebbia, Antonio D'Aquino, Claudia Garipoli, Giuseppe Altavilla, Rafael Rosell. Transl Lung Cancer Res 2021
0

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Lung Cancer (Auckl) 2021
0

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Leylah M Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka V Ikpeazu. J Hematol Oncol 2021
0

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Julia K Rotow, Philippe Gui, Wei Wu, Victoria M Raymond, Richard B Lanman, Frederic J Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B Corcoran,[...]. Clin Cancer Res 2020
24


Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
38

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Philippe Jamme, Marie Fernandes, Marie-Christine Copin, Clotilde Descarpentries, Fabienne Escande, Angela Morabito, Valérie Grégoire, Matthieu Jamme, Simon Baldacci, David Tulasne,[...]. J Thorac Oncol 2020
22

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Caiwen Huang, Qihua Zou, Hui Liu, Bo Qiu, Qiwen Li, Yongbin Lin, Ying Liang. Curr Treat Options Oncol 2020
8

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip. Cancer Treat Rev 2020
18

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.
Joon Young Hur, Bo Mi Ku, Joon Ho Shim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. In Vivo 2020
3

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
99

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
18